Inhibition of proto-oncogene c-src tyrosine kinase: Toward a new antiarrhythmic strategy?

Journal of the American College of Cardiology

Volumn 63, Issue 9, 2014, Pages 935-937

  Mestroni, Luisa ^a   Nguyen, Duy Thai ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

connexin43; gap junctions; myocardial infarction; Src; sudden death

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CONNEXIN 43; PROTEIN TYROSINE KINASE; SARACATINIB; PROTEIN KINASE P60;

ARRHYTHMOGENESIS; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART CONDUCTION; HEART INFARCTION; HUMAN; MOLECULAR DYNAMICS; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; CORONARY ARTERY LIGATION; ENZYME ACTIVATION; GAP JUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HYPERTENSION; MUSCLE CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; ROUS SARCOMA ONCOVIRUS; SIGNAL TRANSDUCTION; UPREGULATION;

CONNEXIN43; GAP JUNCTIONS; MYOCARDIAL INFARCTION; SRC; SUDDEN DEATH;

ANIMALS; ARRHYTHMIAS, CARDIAC; CONNEXIN 43; GENE EXPRESSION REGULATION; MALE; MYOCARDIAL INFARCTION; SRC-FAMILY KINASES;

EID: 84895543508     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.082     Document Type: Editorial

References (33)

1. R. Roskoski Jr. Src protein-tyrosine kinase structure and regulation Biochem Biophys Res Commun 324 2004 1155 1164
2. R. Roskoski Jr. Src kinase regulation by phosphorylation and dephosphorylation Biochem Biophys Res Commun 331 2005 1 14
3. G.S. Martin The hunting of the Src Nat Rev Mol Cell Biol 2 2001 467 475
4. F. Kieken, N. Mutsaers, and E. Dolmatova et al. Structural and molecular mechanisms of gap junction remodeling in epicardial border zone myocytes following myocardial infarction Circ Res 104 2009 1103 1112
5. E.C. Beyer, D.L. Paul, and D.A. Goodenough Connexin family of gap junction proteins J Membr Biol 116 1990 187 194
6. D.E. Gutstein, G.E. Morley, and H. Tamaddon et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43 Circ Res 88 2001 333 339
7. N.J. Severs, E. Dupont, and S.R. Coppen et al. Remodelling of gap junctions and connexin expression in heart disease Biochim Biophys Acta 1662 2004 138 148
8. B.N. Giepmans, and W.H. Moolenaar The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein Curr Biol 8 1998 931 934
9. J.M. Rhett, J. Jourdan, and R.G. Gourdie Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1 Mol Biol Cell 22 2011 1516 1528
10. B.N. Giepmans, T. Hengeveld, F.R. Postma, and W.H. Moolenaar Interaction of c-Src with gap junction protein connexin-43. Role in the regulation of cell-cell communication J Biol Chem 276 2001 8544 8549
11. A.A. Sovari, S. Iravanian, and E. Dolmatova et al. Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death J Am Coll Cardiol 58 2011 2332 2339
12. N.S. Peters, J. Coromilas, N.J. Severs, and A.L. Wit Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia Circulation 95 1997 988 996
13. C.A. Rutledge, F.S. Ng, and M.S. Sulkin et al. c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction J Am Coll Cardiol 63 2014 928 934
14. J. Baselga, A. Cervantes, and E. Martinelli et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors Clin Cancer Res 16 2010 4876 4883
15. L.F. Hennequin, J. Allen, and J. Breed et al. N-(5-chloro-1,3- benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran- 4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J Med Chem 49 2006 6465 6488
16. I.D. Greener, T. Sasano, and X. Wan et al. Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction J Am Coll Cardiol 60 2012 1103 1110
17. W. Roell, T. Lewalter, and P. Sasse et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia Nature 450 2007 819 824
18. M.J. Yuan, H. Huang, and Y.H. Tang et al. Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction in rats Peptides 32 2011 2357 2361
19. M. Amino, K. Yoshioka, and D. Fujibayashi et al. Year-long upregulation of connexin43 in rabbit hearts by heavy ion irradiation Am J Physiol Heart Circ Physiol 298 2010 H1014 H1021
20. M. Amino, K. Yoshioka, and T. Tanabe et al. Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction Cardiovasc Res 72 2006 412 421
21. L. Marquez-Rosado, J.L. Solan, C.A. Dunn, R.P. Norris, and P.D. Lampe Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues Biochim Biophys Acta 1818 2012 1985 1992
22. A.P. Moreno, and A.F. Lau Gap junction channel gating modulated through protein phosphorylation Prog Biophys Mol Biol 94 2007 107 119
23. P.D. Lampe, and A.F. Lau The effects of connexin phosphorylation on gap junctional communication Int J Biochem Cell Biol 36 2004 1171 1186
24. J.L. Solan, and P.D. Lampe Connexin43 phosphorylation: structural changes and biological effects Biochem J 419 2009 261 272
25. S. Kanno, A. Kovacs, K.A. Yamada, and J.E. Saffitz Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice J Am Coll Cardiol 41 2003 681 686
26. D.W. Laird, K.L. Puranam, and J.P. Revel Turnover and phosphorylation dynamics of connexin43 gap junction protein in cultured cardiac myocytes Biochem J 273 1991 67 72
27. V.M. Berthoud, P.J. Minogue, J.G. Laing, and E.C. Beyer Pathways for degradation of connexins and gap junctions Cardiovasc Res 62 2004 256 267
28. D.J. Lenihan, and P.R. Kowey Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Oncologist 18 2013 900 908
29. D.R. Shah, R.R. Shah, and J. Morganroth Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy Drug Saf 36 2013 413 426
30. R.R. Shah, J. Morganroth, and D.R. Shah Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval) Drug Saf 36 2013 295 316
31. D.J. Renouf, M.J. Moore, and D. Hedley et al. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer Invest New Drugs 30 2012 779 786
32. H.J. Mackay, H.J. Au, and E. McWhirter et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium Invest New Drugs 30 2012 1158 1163
33. M.G. Fury, S. Baxi, and R. Shen et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) Anticancer Res 31 2011 249 253